Venrock healthcare survey shows pessimism on drug pricing


Orhpan Drugs Pills VC
Many colorful pills and capsules falling on white background. 3d render. Photo courtesy of Artfoliophoto/iStock/Getty Images.

Skepticism remains high that the drug pricing debate will lead to action despite the FDA vowing to combat high drug prices. That was one of the findings in a survey of 300 healthcare experts conducted by the venture firm Venrock. A majority of those polled said that they believe there will still be more talk than action on prescription drug prices, with 19 percent believing that nothing will happen with prescription drug prices.

Among the other findings of the second annual survey: AI is overhyped, with only 7 percent anticipating success in AI in healthcare this year. In addition, 73 percent of respondents felt that the Amazon-Berkshire Hathaway-JPMorgan Chase partnership was going to face substantial challenges and take lots of time.

A PDF of the survey results are available at hcprognosis2018.venrock.com.

Photo of pills and capsules falling courtesy of Artfoliophoto/iStock/Getty Images.

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.